Jennison Associates
MRTX

Jennison Associates’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Jennison Associates’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-80,000
Closed -$6.23M – 686
2019
Q3 		$6.23M Hold
80,000
– – 0.01% 446
2019
Q2 		$8.24M Buy
+80,000
New +$6.23M 0.01% 451

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates's MRTX Position: Q1 2022 in Review

Jennison Associates sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022, closing a stake of 257,939 shares — an estimated $37.8M sold.

Jennison Associates first reported a position in MRTX in Q3 2015 and held it in 18 quarters. The position peaked at $99.6M in Q2 2019. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

  • Jennison Associates reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Jennison Associates sold 257,939 Mirati Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $37.8M.
  • Jennison Associates first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 18 quarters.
  • Jennison Associates's Mirati Therapeutics, Inc. Common Stock position peaked at $99.6M in Q2 2019.
  • 253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Jennison Associates's 13F filing for Q1 2022, filed 11 May 2022.